Two cell population comprising chondrocyte precursors and human embryonic stem cells
This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.
1. Two cell populations, comprising a differentiated in vitro cell population comprising at least 5% cells that synthesize either Type II collagen or aggrecan from an endogenous gene, and the undifferentiated human embryonic stem (hES) cell line from which it was obtained.
2. Two cell populations comprising:
a) a first cell population obtained by differentiating in vitro a portion of a population of primate pluripotent stem cells expressing the markers stage specific embryonic antigen 3 (SSEA 3), stage specific embryonic antigen 4 (SSEA 4), Tra,1-60 and Tra-I-81, in which at least 5% of the cells in the first cell population synthesize either Type II collagen or aggrecan from an endogenous gene; and
b) a second cell population comprising a cell expressing the markers stage specific embryonic antigen 3 (SSEA 3), stage specific embryonic antigen 4 (SSEA 4), Tra,1-60 and Tra-I-81 from which the first population was obtained.
3. A method of differentiating a primate pluripotent stem (pPS) cell into a cell expressing collagen II or aggrecan comprising
a) forming an embryoid body; and
b) culturing the embryoid body in a growth environment comprising a differentiation mix comprising one or more of transforming growth factor (TGF),fibroblast growth factor (FGF), growth differentiation factor (GDF), bone morphogenic protein (BMP), hedgehog protein, L-ascorbic acid and para-thyroid hormone related protein.
4. The method of claim 3 , wherein the transforming growth factor is chosen from TGFβ1, TGFβ2, TGFβ3.
5. The method of claim 3 wherein the transforming growth factor is TGFβ3.
6. The method of claim 3 , wherein the transforming growth factor is TGFβ1.
7. The method of claim 3 , wherein the growth environment further comprises insulin like growth factor.